CY1122136T1 - Σταθεροποιημενη σουλφοραφανη - Google Patents

Σταθεροποιημενη σουλφοραφανη

Info

Publication number
CY1122136T1
CY1122136T1 CY20191100897T CY191100897T CY1122136T1 CY 1122136 T1 CY1122136 T1 CY 1122136T1 CY 20191100897 T CY20191100897 T CY 20191100897T CY 191100897 T CY191100897 T CY 191100897T CY 1122136 T1 CY1122136 T1 CY 1122136T1
Authority
CY
Cyprus
Prior art keywords
sulforaphane
stabilized sulforaphane
stabilized
cyclodextrin
analog
Prior art date
Application number
CY20191100897T
Other languages
English (en)
Inventor
Ido Dov Dagan
Albert Roger Frisbee
Peter Wyatt Newsome
Michel Pierre Baudet
Original Assignee
Pharmagra Labs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39641899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122136(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmagra Labs, Inc. filed Critical Pharmagra Labs, Inc.
Publication of CY1122136T1 publication Critical patent/CY1122136T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/18—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms
    • C07C331/20—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/26—Isothiocyanates having isothiocyanate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/025—Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Παρέχεται μία μέθοδος σταθεροποίησης της σουλφοραφάνης. Η μέθοδος περιλαμβάνει την επαφή σουλφοραφάνης ή ενός αναλόγου αυτής και μιας κυκλοδεξτρίνης ώστε να σχηματιστεί ένα σύμπλοκο μεταξύ της σουλφοραφάνης ή αναλόγου αυτής και της κυκλοδεξτρίνης.
CY20191100897T 2007-01-23 2019-08-21 Σταθεροποιημενη σουλφοραφανη CY1122136T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88187507P 2007-01-23 2007-01-23
EP08724719A EP2120969A4 (en) 2007-01-23 2008-01-23 STABILIZED SULFORAPHANE
PCT/US2008/000832 WO2008091608A1 (en) 2007-01-23 2008-01-23 Stabilized sulforaphane
EP14166888.9A EP2796140B1 (en) 2007-01-23 2008-01-23 Stabilized Sulforaphane

Publications (1)

Publication Number Publication Date
CY1122136T1 true CY1122136T1 (el) 2020-11-25

Family

ID=39641899

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100897T CY1122136T1 (el) 2007-01-23 2019-08-21 Σταθεροποιημενη σουλφοραφανη

Country Status (17)

Country Link
US (1) US7879822B2 (el)
EP (4) EP2120969A4 (el)
JP (4) JP2010516766A (el)
AU (1) AU2008209543B2 (el)
CA (1) CA2672971C (el)
CY (1) CY1122136T1 (el)
DK (2) DK3354267T3 (el)
ES (2) ES2743043T3 (el)
HK (2) HK1199407A1 (el)
HR (1) HRP20191495T1 (el)
HU (2) HUE046151T2 (el)
LT (1) LT3354267T (el)
PL (2) PL3354267T3 (el)
PT (1) PT3354267T (el)
SI (1) SI3354267T1 (el)
TR (1) TR201808561T4 (el)
WO (1) WO2008091608A1 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046151T2 (hu) * 2007-01-23 2020-02-28 Pharmagra Labs Inc Stabilizált szulforafán
WO2010065329A2 (en) * 2008-11-25 2010-06-10 The Board Of Regents Of The University Of Texas System Nanoparticles for cancer treatment
BE1019434A3 (fr) * 2010-07-23 2012-07-03 Auriga Internat Stabilisation du sulforaphane.
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
US10925934B2 (en) 2011-02-22 2021-02-23 Caudill Seed and Warehouse Co., Inc. Spray dried myrosinase and use to produce isothiocynates
ES2425294B1 (es) * 2012-03-09 2014-09-02 Consejo Superior De Investigaciones Científicas (Csic) Compuestos derivados de sulforafano, método de obtención y su uso médico, alimenticio y cosmético
CN102697764A (zh) * 2012-05-03 2012-10-03 苏州纳晶医药技术有限公司 一种含有异硫氰酸苯乙酯的肠溶固体制剂
PL2854861T3 (pl) * 2012-06-01 2018-02-28 Pharmagra Labs Inc Sposób syntetyzowania sulforafanu
CN104640573B (zh) * 2012-06-01 2017-08-01 法玛格拉实验室公司 萝卜硫烷的分离和纯化
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
WO2014018874A1 (en) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Method for treating skin cancer
DE102014012367B3 (de) * 2014-08-25 2015-08-27 De Smaakmaker Holding B. V. Verfahren zum Bestimmen der Konzentration von Glucoraphanin und/oder von Sulforaphan in einer Pflanze
CN107468666B (zh) * 2017-08-18 2021-01-01 赣州华汉生物科技有限公司 一种可稳定保存的萝卜硫素胶囊及其制备方法
CA3090188A1 (en) * 2018-02-02 2019-08-08 Commonwealth Scientific And Industrial Research Organisation Protecting a bioactive and/or precursor thereof
GB2574248B (en) * 2018-05-31 2021-03-03 Edwards Ltd Foreline for a vacuum pump
KR102457241B1 (ko) * 2020-02-26 2022-10-21 경일대학교산학협력단 페닐이소티오시아네이트를 처리하여 십자화과 식물로부터 설포라판을 생산하는 방법 및 보존하는 방법
GB202005238D0 (en) * 2020-04-08 2020-05-20 Evgen Pharma Plc Crystalline complexes
US20230150932A1 (en) 2020-04-23 2023-05-18 Vio Chemicals Ag Compositions for stabilizing an isothiocyanate
WO2023037934A1 (ja) * 2021-09-13 2023-03-16 富士フイルム株式会社 ビシクロアルカン化合物の包摂体の製造方法
CN113908294B (zh) * 2021-11-02 2023-09-12 成都格纯生物医药有限公司 一种含花椰菜精制提取物的双包合物的制备方法和应用
WO2023133494A2 (en) * 2022-01-06 2023-07-13 Brassica Protection Products Llc Oil-based isothiocyanate products and processes for preparing oil-based isothiocyanate products

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669984A (en) * 1900-02-06 1901-03-19 Josef Federmann Spittoon.
US673744A (en) * 1900-08-06 1901-05-07 Pearl M Westerfield Vending-box.
US5458903A (en) * 1993-01-19 1995-10-17 The Pillsbury Company High fat biscuit mix and products resulting therefrom
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
JP3604172B2 (ja) * 1994-03-22 2004-12-22 株式会社白元 除菌組成物、及び除菌方法
US5589504A (en) 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
US6117429A (en) 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
FR2776666B1 (fr) 1998-03-31 2002-09-06 Commissariat Energie Atomique Complexes d'inclusion dans des cyclodextrines d'isothiocyanates organiques, en particulier bacteriostatiques, bactericides et/ou fongicides ou de leurs precurseurs naturels, et leur preparation
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
EP1109806B8 (en) 1999-07-01 2003-10-29 Italfarmaco S.p.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivates
US6361812B1 (en) 1999-11-18 2002-03-26 The Procter & Gamble Co. Products comprising an isothiocyanate preservative system and methods of their use
KR20020063914A (ko) 1999-12-20 2002-08-05 코니스 프랑스, 에스.에이. 화장용 및/또는 약학용 제제
US6433011B1 (en) 2000-03-08 2002-08-13 American Health Foundation Method for inhibiting formation of aberrant crypt foci in the colon of a mammal
JP2002051732A (ja) 2000-06-12 2002-02-19 Access Business Group Llc 食事による植物性化学物質欠乏症を矯正する組成物及び方法
WO2002002190A2 (en) 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
US6737441B2 (en) 2000-08-21 2004-05-18 Jed W. Fahey Treatment of helicobacter with isothiocyanates
JP2002187842A (ja) * 2000-12-19 2002-07-05 Toyo Shinyaku:Kk ケール加工品およびその加工方法
JP2003146803A (ja) * 2001-11-13 2003-05-21 Carex Inc 抗菌性粉末組成物およびその製造方法
CA2603235A1 (en) * 2005-03-28 2006-10-05 Bioresponse, Llc Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
FR2888235B1 (fr) * 2005-07-07 2007-09-14 Nutrinov Sa Procede d'extraction de sulforaphane a partir de broyat de crucifere contenant de la glucoraphanine
CN101120948A (zh) * 2006-08-08 2008-02-13 普文英 一种具有化学保护、癌症预防和治疗用途的化合物组合物
HUE046151T2 (hu) * 2007-01-23 2020-02-28 Pharmagra Labs Inc Stabilizált szulforafán

Also Published As

Publication number Publication date
HRP20191495T1 (hr) 2019-11-29
ES2743043T3 (es) 2020-02-18
JP6677688B2 (ja) 2020-04-08
CA2672971A1 (en) 2008-07-31
PL3354267T3 (pl) 2019-11-29
EP2796140A3 (en) 2014-12-24
JP2016145218A (ja) 2016-08-12
EP2796140A2 (en) 2014-10-29
LT3354267T (lt) 2019-09-25
EP3354267A1 (en) 2018-08-01
US7879822B2 (en) 2011-02-01
EP2120969A4 (en) 2010-06-02
JP2010516766A (ja) 2010-05-20
EP2120969A1 (en) 2009-11-25
CA2672971C (en) 2014-03-11
EP2796140B1 (en) 2018-05-02
PL2796140T3 (pl) 2018-09-28
AU2008209543B2 (en) 2014-03-13
AU2008209543A1 (en) 2008-07-31
DK2796140T3 (en) 2018-06-25
SI3354267T1 (sl) 2019-11-29
TR201808561T4 (tr) 2018-07-23
JP2018027956A (ja) 2018-02-22
PT3354267T (pt) 2019-09-10
JP2014055140A (ja) 2014-03-27
DK3354267T3 (da) 2019-08-26
EP3354267B1 (en) 2019-08-07
WO2008091608A1 (en) 2008-07-31
JP6566886B2 (ja) 2019-08-28
EP2532352A1 (en) 2012-12-12
HK1199407A1 (en) 2015-07-03
HUE039549T2 (hu) 2019-01-28
US20080176942A1 (en) 2008-07-24
HK1258801A1 (zh) 2019-11-22
ES2674052T3 (es) 2018-06-27
HUE046151T2 (hu) 2020-02-28

Similar Documents

Publication Publication Date Title
CY1122136T1 (el) Σταθεροποιημενη σουλφοραφανη
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
ECSP13012784A (es) Anticuerpos anti-mesotelina e inmunoconjugados
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
CY1113074T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CR20120183A (es) PIPERIDINAS SUSTITUIDAS QUE AUMENTAN LA ACTIVIDAD DE p53 Y SUS USOS
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
UY34887A (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
BR112015032224A2 (pt) anticorpos anti-fcrh5
CR20120577A (es) Anticuerpos hacia gdf8 humano
BRPI0921805A2 (pt) anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor
PA8850101A1 (es) Combinaciones antitumorales que contienen anticuerpos
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
ATE541597T1 (de) Implantierbare vorrichtung mit sich langsam auflösendem polymer
NI201001032A (es) Formas crsitalinas de dimetoxi docetaxel y metodo para preparar el mismo.
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
PA8849901A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y la citarabina
BRPI0810744A2 (pt) Moléculas absorventes de oxigênio, objetos que as contêm, e métodos de sua utilização
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες